Latest news with #OptiscanImaging
Sydney Morning Herald
2 days ago
- Business
- Sydney Morning Herald
Melbourne breast cancer trial to test Optiscan imaging device
ASX-listed medical technology company Optiscan Imaging has started recruiting up to 50 patients for a Royal Melbourne Hospital clinical trial of its innovative precision surgery and digital pathology imaging devices, aiming to improve a common breast cancer surgery. The groundbreaking clinical study will utilise Optiscan's InVue microscopic precision surgery device, as well as its InForm digital pathology imaging system, to create a new, improved treatment regimen for breast cancer patients. The company will investigate the clinical workflow and real-time imaging capabilities of the two platforms in its first in-human breast cancer study. Optiscan will use data from the trial in its submissions for United States Food and Drug Administration (FDA) registration for the devices. Surgeons will use the InVue device during surgery to capture live imaging data from a woman's breast tissue after removing a tumour. It will provide the surgical team with immediate feedback on tumour clearance, ensuring there is a margin of healthy breast tissue around the site where the tumour was removed. Achieving a clear surgical margin, where no cancerous cells are left at the edges of the removed tissue, is critical to a patient's long-term health outcome but poses a significant surgical challenge. 'We believe our innovative real-time microscopic imaging platform represents a genuine breakthrough in surgical cancer management by bringing live cellular imaging to the bedside.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah Using topical dyes, the removed tissue will then be examined with the InForm device to back up the InVue imaging. The additional InForm pathology data will be fed back into the company's imaging and pathology workflows ahead of its FDA application. The study will also incorporate InForm imaging of tissue samples taken chairside or from pathology laboratories to match its other ex vivo patient data. InForm can assess new tissue samples quickly and accurately with high resolution and magnification. While each device was designed to operate independently, Optiscan says it purposefully included both in the trial to maximise data collection, minimise the need to recruit patients into further trials and accelerate its regulatory submissions.
The Age
2 days ago
- Business
- The Age
Melbourne breast cancer trial to test Optiscan imaging device
ASX-listed medical technology company Optiscan Imaging has started recruiting up to 50 patients for a Royal Melbourne Hospital clinical trial of its innovative precision surgery and digital pathology imaging devices, aiming to improve a common breast cancer surgery. The groundbreaking clinical study will utilise Optiscan's InVue microscopic precision surgery device, as well as its InForm digital pathology imaging system, to create a new, improved treatment regimen for breast cancer patients. The company will investigate the clinical workflow and real-time imaging capabilities of the two platforms in its first in-human breast cancer study. Optiscan will use data from the trial in its submissions for United States Food and Drug Administration (FDA) registration for the devices. Surgeons will use the InVue device during surgery to capture live imaging data from a woman's breast tissue after removing a tumour. It will provide the surgical team with immediate feedback on tumour clearance, ensuring there is a margin of healthy breast tissue around the site where the tumour was removed. Achieving a clear surgical margin, where no cancerous cells are left at the edges of the removed tissue, is critical to a patient's long-term health outcome but poses a significant surgical challenge. 'We believe our innovative real-time microscopic imaging platform represents a genuine breakthrough in surgical cancer management by bringing live cellular imaging to the bedside.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah Using topical dyes, the removed tissue will then be examined with the InForm device to back up the InVue imaging. The additional InForm pathology data will be fed back into the company's imaging and pathology workflows ahead of its FDA application. The study will also incorporate InForm imaging of tissue samples taken chairside or from pathology laboratories to match its other ex vivo patient data. InForm can assess new tissue samples quickly and accurately with high resolution and magnification. While each device was designed to operate independently, Optiscan says it purposefully included both in the trial to maximise data collection, minimise the need to recruit patients into further trials and accelerate its regulatory submissions.
The Age
10-06-2025
- Business
- The Age
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Sydney Morning Herald
10-06-2025
- Business
- Sydney Morning Herald
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Sydney Morning Herald
27-05-2025
- Business
- Sydney Morning Herald
Optiscan software breakthrough will bring pathologists to the bedside
ASX-listed medical technology innovator Optiscan Imaging has just fired a major shot across the bow of the global diagnostics industry with the launch of its game-changing cloud-based telepathology platform prototype. The company confirmed it has reached the minimum viable product (MVP) stage for its secure streaming software, developed in collaboration with Canadian software firm Prolucid Technologies. Successful beta-testing of the new software means pathologists could soon dial in from anywhere in the world to stream live, high-resolution tissue scans captured by clinicians in real time via a secure cloud connection - whether a hospital theatre, remote clinic or a clinician in the deep Outback. In addition to viewing images, pathologists will be able to flag key areas, annotate pictures, generate reports and collaborate with surgeons or imaging specialists live or on demand. 'This platform is a potential game changer for global digital pathology.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah The platform is designed to integrate seamlessly with Optiscan's range of digital imaging devices, including the company's InVue, InForm and InVivage systems. Optiscan Imaging chief executive officer and managing director Dr Camile Farah said: 'This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural and remote healthcare settings where access to pathology expertise is limited. Our telepathology solution essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology.' Optiscan says security is top of mind. All communications are encrypted, with personal patient data hidden or made anonymous. Only registered devices with valid digital certificates can access the system, which uses a WebRTC-based protocol to keep the upload lag time under half a second. The system has been designed as a Software as a Medical Device (SaMD), meaning it's ready to slot into everyday clinical use. It will let doctors stream images directly to each other, review scans later, share second opinions and generate reports - all while keeping patient data safe and secure.
